Paul G. Richardson

Paul G. Richardson, MD, is a RJ Corman Professor of Medicine at Harvard Medical School, Clinical Program Leader and Director of Clinical Research at Jerome Lipper Multiple Myeloma Center at Dana-Faber Cancer Institute in USA, and an Institute Physician.

After certification in Internal Medicine, Hematology and Medical Oncology, as well as working in Cancer Pharmacology from 1994 onwards at Dana-Farber Cancer Institute (DFCI), Dr. Paul Richardson joined the Jerome Lipper Myeloma Center in 1999, was appointed Clinical Director in 2001, and led the development of several first-generation novel drugs including bortezomib, lenalidomide and pomalidomide for the treatment of multiple myeloma.
Over the last decade, his major effort has been focused on the development of lenalidomide, bortezomib and dexamethasone (so-called RVD), and its incorporation as part of the Intergroup Francophone Myelome (IFM)/DFCI clinical trial in newly diagnosed patients eligible for stem cell transplant treated with RVD.

He has published extensively, having authored or co-authored over 450 original articles and 375 reviews, chapters, and editorials in peer-reviewed journals.